↓ Skip to main content
  1. Resources/
  2. Assets/

NAM vs Animal Testing TP

1921 words·10 mins
Table of Contents

NAM vs Animal Testing
#

Across three critical domains - Science, Ethics, and Efficiency - NAM consistently outperform the obsolete animal testing model.

alt
Talking about NAM
Credit: wal_172619 (pixabay)
Category NAM Animal Testing
Science Human-relevant data. Leverages organ-on-a-chip, in silico modeling, and AI to directly replicate human biology.1 2 3 Interspecies barrier. Relies on non-human biology; inherently fails to predict human-specific physiological outcomes.4 5 6
Ethics No animal suffering. Aligns scientific innovation with universal standards of non-violence and ethical responsibility.7 8 Systemic exploitation. Inflicts severe harm and death on millions of sentient animals annually; out of step with modern values.9 10
Efficiency High-speed, scalable. Accelerates discoveries via high-throughput screening, delivering precise data in days or weeks.11 Stagnant, cost-prohibitive. Drains resources via multi-year observational timelines and massive animal facility overhead.12

Strategic Callouts
#

For Scientists
#

Produce data that actually applies to humans. Years of comparative data published in peer-reviewed journals demonstrate that NAM consistently out-predicts traditional animal models. Transitioning to human-centric platforms eliminates false leads, reduces clinical attrition, and aligns your laboratory with modern biomedical innovation.

For Policymakers
#

Secure scientific autonomy and competitiveness. While the United States (via the FDA Modernization Act 2.0) and the European Union actively fund and legislate the phase-out of animal models, Canadian regulatory frameworks remain dangerously stagnant. Modernizing public funding to mandate NAM infrastructure is a matter of national economic and scientific survival.

For Educators and Youth
#

Train for the future, not the past. Animal dissection and traditional toxicological assays are obsolete methodologies. Equipping the next generation with computational biology, tissue engineering, and machine learning skillsets is essential for global career readiness in 21st-century biotechnology.

Frequently Asked Questions
#

Why are animal models failing scientifically?
#

Animal testing suffers from a catastrophic translation failure—approximately 90% to 95% of drugs that pass animal trials fail in human clinical trials because species-specific biology cannot predict human physiology. NAM utilizes human-derived cells, computational biology, and machine learning, replacing flawed surrogates with direct human relevance.13

Isn’t animal testing legally mandated?
#

The regulatory landscape has fundamentally shifted. In the US, the FDA Modernization Act 2.0 eliminated the federal mandate requiring animal testing for new drugs, explicitly greenlighting human-relevant NAM. Globally, dozens of nations have banned animal testing for cosmetics and are actively rewriting chemical safety frameworks to favor non-animal methods.14 15

Are NAM more expensive than animal research?
#

No. Animal testing is an immense financial drain - it requires years of animal maintenance, breeding, and slow observational protocols. NAM offers rapid, high-throughput screening that delivers data in days or weeks rather than years. The long-term economic savings in drug development speed and reduced clinical trial failures are measured in billions of dollars.16

What concrete technologies define NAM?
#

NAM comprises a sophisticated suite of advanced scientific tools17 such as:

  • Microphysiological Systems (MPS) - “Organ-on-a-chip” devices that replicate the mechanical and biochemical functions of living human organs.
  • In Silico Modeling and AI - Advanced computational simulations that predict toxicity and molecular interactions using massive human datasets.
  • Human Organoids - Three-dimensional tissue cultures grown from human stem cells that mimic complex organ architecture.
  • 3D Bioprinting - Uses 3D printing techniques to create living tissues and organs by combining cells, growth factors, and biomaterials in a layer-by-layer process.
  • High-Throughput Screening - Automated robotic systems capable of testing thousands of chemical compounds simultaneously on human cellular assays. The development of CRISPR gene-editing is a well-known example.

Many breakthroughs have been made as a result of NAM.18

How do NAM compare in predictive reliability?
#

NAM routinely outperforms animal models in accuracy. Traditional animal assays for skin sensitization or systemic toxicity often hover around 50% to 60% reproducibility - essentially a coin flip. In contrast, validated human-predictive NAM consistently achieve accuracy rates exceeding 80% to 90% because they eliminate inter-species biological variance.19 20

How can I actively accelerate the transition to NAM?
#

True progress requires systemic advocacy21:

  • Academic Reform - Push for the integration of NAM into university/school science curricula to phase out obsolete animal dissection and testing labs.
  • Policy Support - Demand dedicated government funding for public infrastructure, validation centers, and research grants exclusively for NAM.
  • Public Awareness - Distribute this brief, deploy the digital assets, and direct researchers, students, and policymakers to the open-access resources at pnars.org website22 23.

Can I print this document?
#

This Talking Point is available for download right here.

Footnotes
#

  1. Organ-on-a-chip meets artificial intelligence in drug evaluation. Theranostics, 13(13), 4526-4558.   Reviews how the convergence of artificial intelligence and microfluidic organ-on-a-chip (OoC) platforms enhances physiological relevance, optimizes tissue-tissue interactions, and dramatically improves human-specific drug evaluation accuracy over non-human models. ↩︎

  2. In silico modelling of organ-on-a-chip devices: an overview. Frontiers in Bioengineering and Biotechnology, 12, Article 1520795.   Details how mathematical and computational (in silico) simulations are paired with physical microfluidic devices (like lung, liver, and kidney chips) to predict human physiological outcomes, optimize experimental conditions, and eliminate traditional testing overhead. ↩︎

  3. New approach methodologies (NAMs): identifying and overcoming hurdles to accelerated adoption. Toxicology Research, 13(2), Article tfae044.   Industry reference that establishes how NAM (including computational toxicology, in vitro screens, and multi-omics) provide more protective, human-relevant chemical safety data than historical mammalian assays. ↩︎

  4. Analysis of animal-to-human translation shows that only 5% of animal-tested therapeutic interventions obtain regulatory approval for human applications   While this 2024 umbrella review notes that early-stage animal and human trials often appear to agree due to systemic publication biases, it confirms the brutal bottom line: 95% of animal-tested therapies completely fail to achieve human regulatory approval. ↩︎

  5. The flaws and human harms of animal experimentation. Cambridge Quarterly of Healthcare Ethics, 24(4), 407-419.   Foundational, heavily cited text in non-animal advocacy literature that systematically outlines the anatomical, genetic, and metabolic differences that cause the interspecies barrier to fail human patients. ↩︎

  6. Is it possible to overcome issues of external validity in preclinical animal research? Why most animal models are bound to fail. Journal of Translational Medicine, 16, 304 (2018).   The pharmaceutical industry faces a critical productivity crisis driven by dismal translation rates from bench to bedside. This failure is primarily attributed to preclinical animal models poorly predicting clinical efficacy and safety. ↩︎

  7. With What Should We Replace Nonhuman Animals in Biomedical Research Protocols?   The historical ethical framework of merely “reducing” or “refining” animal testing is an obsolete paradigm. True scientific and moral progress requires the outright replacement of animal protocols with human-relevant models to stop the alarming failure rate of drug translation. ↩︎

  8. Critical Animal Studies and Animal Law. Animal Law Review, 18(2), 207-236 (2012).
    Law is fundamentally anthropocentric, treating sentient beings as mere property. Integrating critical animal studies into legal frameworks is necessary to challenge the state-sanctioned species hierarchy and expose how the system erases non-human victimhood to protect corporate interests. ↩︎

  9. An Estimate of the Number of Animals Used for Scientific Purposes Worldwide in 2015. Alternatives to Laboratory Animals, 48(3), 135-143 (2020).
    A rigorous statistical analysis establishing that an estimated 192 million sentient animals are used annually in scientific procedures worldwide. This massive scale of hidden exploitation highlights the urgent need for systemic regulatory overhauls and global replacement strategies. ↩︎

  10. Public Attitudes toward the Use of Animals in Research: Effects of Species, Justification and Harm. Animals, 4(3), 391-406 (2014).
    A comprehensive evaluation of public opinion trends demonstrating a profound, structural shift in modern societal values as early as 2014. Institutional acceptance of animal experimentation is further collapsing as public moral standards increasingly reject the infliction of systemic harm on sentient beings. ↩︎

  11. High-Throughput Screening - an overview. ScienceDirect Topics.
    Automated high-throughput screening (HTS) platforms fundamentally redefine research efficiency. By evaluating thousands of chemical compounds simultaneously on human cellular assays, these robotic systems deliver precise toxicity and efficacy profiles on a massive scale, compressing multi-year animal testing timelines into mere days or weeks. ↩︎

  12. Why Are Monoclonal Antibodies the First Prime Targets for Animal-Free Testing at FDA? Animal Wellness Action.
    Live animal research imposes immense financial and logistical burdens. Comparative cost analyses demonstrate that a standard preclinical evaluation utilizing animal-free organ-chips costs roughly $325,000, compared to over $5.2 million for identical protocols using non-human primates, representing a dramatic reduction in resource consumption. ↩︎

  13. Will Non-Animal Approaches Replace Some or All of Animal Testing? Charles River Laboratories Eureka.
    The average cost to bring a single new drug to market scales to $2.6 billion, with a massive portion trapped in slow, preclinical mammalian facility overhead. This astronomical resource drain is structurally inefficient, given that over 92% of compounds clearing these protracted animal pipelines ultimately fail in human clinical trials due to fundamental interspecies barriers. ↩︎

  14. The Future is Animal-Free: Accelerating Humane and Human-Relevant Science. European Coalition to End Animal Experiments (ECEAE) Report.
    A comprehensive policy report documenting that between 90% and 95% of drugs found to be safe and effective in preclinical animal tests ultimately fail in human clinical trials due to profound, insurmountable biological and physiological species barriers. ↩︎

  15. Why TPI - Transition Programme for Innovation Without the Use of Animals (TPI). Dutch Ministry of Agriculture, Fisheries, Food Security and Nature.
    The official framework of the Dutch government’s national strategy to position the Netherlands as a global frontrunner in animal-free science. The interministerial initiative formally establishes national policies to systematically phase out animal procedures by accelerating the qualification, regulatory acceptance, and deployment of human-relevant alternatives like organs-on-a-chip and artificial intelligence. ↩︎

  16. Cost of drug development. Wikipedia.
    A comprehensive aggregate analysis tracking the massive capital investments required for therapeutic pipelines, documenting that average expenditures range from hundreds of millions to several billion dollars per successful asset. The structural timeline inefficiencies and high attrition rates of legacy preclinical protocols serve as a primary macroeconomic driver of these astronomical costs. ↩︎

  17. What are NAMs? Science Advancement and Outreach Division (SAO).
    A definitive technical breakdown defining NAM explicitly as non-animal, human-derived methods. The overview outlines the core suite of defining technologies—including 3D human organoids, microfluidic organs-on-chips, computational modeling, non-invasive diagnostic imaging, and human microdosing—which replace flawed animal surrogates with direct human biological relevance. ↩︎

  18. Advances Due to New Approach Methodologies
    New Approach Methodologies (NAM) represent a paradigm shift in biomedical research and drug development, replacing or supplementing traditional animal testing with human-relevant, in vitro, in silico, and in chemico technologies. The sections below synthesize peer-reviewed, validated medical discoveries enabled by NAM, organized thematically under the following areas. ↩︎

  19. A triangular approach for the validation of new approach methods for skin sensitization. ALTEX - Alternatives to Animal Experimentation, 38(4), 608-624 (2021).
    A landmark validation study demonstrating that non-animal defined approaches (DAs) consistently achieve an 85% to 89% accuracy rate in predicting human skin sensitization hazards, routinely outperforming traditional animal assays that exhibit significantly lower reproducibility due to species-specific variance. ↩︎

  20. Integrating New Approach Methodologies (NAMs) into Preclinical Regulatory Evaluation. PMC Oncology Review, Article PMC12730968 (2025).
    A methodological analysis establishing that traditional animal models fail as predictive simulations due to insurmountable species-specific differences in disease biology and pharmacology. The study demonstrates that true predictive validity requires parameterized, human-relevant variables (such as organoids and computational modeling) rather than superficial macro-level organismic resemblances. ↩︎

  21. Socio-technical transitions to sustainability: a review of criticisms and elaborations of the Multi-Level Perspective. Current Opinion in Environmental Sustainability, 39, 187-201 (2019).
    A foundational structural analysis establishing that destabilizing an entrenched socio-technical regime requires coordinated systemic advocacy across multiple spheres—specifically analyzing how political power, institutional policy changes, cultural framing struggles, and grassroots public innovations work together to break historical path-dependency. ↩︎

  22. Resources Altering Ingrained School Education (RAISE)
    Central hub of tools, templates, and resources on the pnars.org website to empower students, parents, and educators in advocating for modern NAM education in Canada. ↩︎

  23. PNARS Resources
    Comprehensive resources including regulatory documents, promotional materials, and educational tools for NAM adoption and understanding. ↩︎